Sarcomatous evolution of oligodendroglioma (" oligosarcoma" ): Confirmatory report of an uncommon pattern of malignant progression in oligodendroglial tumors

Pathology Research and Practice

Volumn 208, Issue 12, 2012, Pages 750-755

  Vajtai, Istvan ^a   Vassella, Erik ^a   Hewer, Ekkehard ^a   Kappeler, Andreas ^a   Reinert, Michael M ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Biphasic neoplasm; Codeletion 1p 19q; IDH1; Oligodendroglial genotype; Oligosarcoma

Indexed keywords

ARGININE; CONTRAST MEDIUM; EPITHELIAL MEMBRANE ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; HISTIDINE; ISOCITRATE DEHYDROGENASE 1; PROTEIN S 100; SMOOTH MUSCLE ACTIN; TEMOZOLOMIDE; VIMENTIN;

ADULT; ARTICLE; BRAIN TUMOR; CASE REPORT; CHROMOSOME 1P; CHROMOSOME BAND; CHROMOSOME DELETION; CONTRAST ENHANCEMENT; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IDH1 GENE; IMMUNOREACTIVITY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROFIBROSARCOMA; OLIGODENDROGLIOMA; SPINDLE CELL; TUMOR GENE; TUMOR GROWTH; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE PROGRESSION; GLIOSARCOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; OLIGODENDROGLIOMA;

EID: 84870297155     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2012.09.009     Document Type: Article

References (29)

1. Bromberg J.E., van den Bent M.J. Oligodendrogliomas: molecular biology and treatment. Oncologist 2009, 14:155-163.
2. Burger P.C. What is an oligodendroglioma?. Brain Pathol. 2002, 12:257-259.
3. Burger P.C., Scheithauer B.W. Tumors of the Central Nervous System. AFIP Atlas of Tumor Pathology, Series 4, Fascicle 7 2007, American Registry of Pathology, Washington, DC.
4. Capper D., Weissert S., Balss J., Habel A., Meyer J., Jäger D., Ackermann U., Tessmer C., Korshunov A., Zentgraf H., Hartmann C., von Deimling A. Characterization of R132H mutation-specific antibody binding in brain tumors. Brain Pathol. 2010, 20:245-254.
5. Capper D., Reuss D., Schittenhelm J., Hartmann C., Bremer J., Sahm F., Harter P.N., Jeibmann A., von Deimling A. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol. 2011, 121:241-252.
6. Feigin I., Ransohoff J., Lieberman A. Sarcoma arising in oligodendroglioma of the brain. J. Neuropathol. Exp. Neurol. 1976, 35:679-684.
7. WHO Classification of Tumours of Soft Tissue and Bone 2002, IARC, Lyon. C.D.M. Fletcher, K.K. Unni, F. Mertens (Eds.).
8. Hasselblatt M., Paulus W. Sensitivity and specificity of epithelial membrane antigen staining patterns in ependymomas. Acta Neuropathol. 2003, 106:385-388.
9. Hattab E.M., Martin S.E., Shapiro S.A., Cheng L. Pleomorphic xanthoastrocytoma and oligodendroglioma: collision of 2 morphologically and genetically distinct anaplastic components. J. Neurosurg. 2011, 114:1648-1653.
10. Hegi M.E., Janzer R.C., Lambiv W.L., Gorlia T., Kouwenhoven M.C.M., Hartmann C., von Deimling A., Martinet D., Besuchet Schmutz N., Diserens A.C., Hamou M.F., Bady P., Weller M., van den Bent M.J., Mason W.P., Mirimanoff R.O., Stupp R., Mokhtari K., Wesseling P. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathol. 2012, 123:841-852.
11. Jentoft M., Giannini C., Rossi S., Mota R., Jenkins R.B., Rodriguez F.J. Oligodendroglial tumors with marked desmoplasia: clinicopathologic and molecular features of 7 cases. Am. J. Surg. Pathol. 2011, 35:845-852.
12. Kaplan K.J., Perry A. Gliosarcoma with primitive neuroectodermal differentiation: case report and review of the literature. J. Neurooncol. 2007, 83:313-318.
13. Kleihues P., Burger P.C., Aldape K.D., Brat D.J., Biernat W., Bigner D.D., Nakazato Y., Plate K.H., Giangaspero F., von Deimling A., Ohgaki H., Cavenee W.K. Glioblastoma. WHO Classification of Tumours of the Central Nervous System 2007, 33-49. IARC, Lyon. D.N. Louis, H. Ohgaki, O.D. Wiestler, W.K. Cavenee (Eds.).
14. Maiuri F., Stella F., Benvenuti D., Giamundo A., Pettinato G. Cerebral gliosarcomas: correlation of computed tomographic findings, surgical aspect, pathological features, and prognosis. Neurosurgery 1990, 26:261-267.
15. Mariani L., Deiana G., Vassella E., Fathi A.R., Murtin C., Arnold M., Vajtai I., Weis J., Siegenthaler P., Schobesberger M., Reinert M.M. Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy. J. Clin. Oncol. 2006, 24:4758-4763.
16. Pasquier B., Couderc P., Pasquier D., Panh M.H., N'Golet A. Sarcoma arising in oligodendroglioma of the brain. A case with intramedullary and subarachnoid spinal metastases. Cancer 1978, 42:2753-2758.
17. Perry A., Scheithauer B.W., Szczesniak D.M., Atkinson J.L., Wald J.T., Hammack J.E. Combined oligodendroglioma/pleomorphic xanthoastrocytoma: a probable collision tumor: case report. Neurosurgery 2001, 48:1358-1361.
18. Perry A., Scheithauer B.W., Macaulay R.J.B., Raffel C., Roth K.A., Kros J.M. Oligodendrogliomas with neurocytic differentiation. A report of 4 cases with diagnostic and histogenetic implications. J. Neuropathol. Exp. Neurol. 2002, 61:947-955.
19. Preusser M., Wöhrer A., Stary S., Höftberger R., Streubel B., Hainfellner J.A. Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J. Neuropathol. Exp. Neurol. 2001, 70:715-723.
20. Rickert C.H., Korshunov A., Paulus W. Chromosomal imbalances in clear cell ependymomas. Mod. Pathol. 2006, 19:958-962.
21. Riemenschneider M.J., Jeuken J.W.M., Wesseling P., Reifenberger G. Molecular diagnostics of gliomas: state of the art. Acta Neuropathol. 2010, 120:567-584.
22. Rodriguez F.J., Scheithauer B.W., Jenkins R., Burger P.C., Rudzinsky P., Vlodavsky E., Schooley A., Landolfi J. Gliosarcoma arising in oligodendroglial tumors (" oligosarcoma" ). A clinicopathologic study. Am. J. Surg. Pathol. 2007, 31:351-362.
23. Rodriguez F.J., Scheithauer B.W., Perry A., Oliveira A.M., Jenkins R.B., Oviedo A., Mork S.J., Palmer C.A., Burger P.C. Ependymal tumors with sarcomatous change (ependymosarcoma): a clinicopathologic and molecular cytogenetic study. Am. J. Surg. Pathol. 2008, 32:699-709.
24. Sahm F., Capper D., Meyer J., Hartmann C., Herpel E., Andrulis M., Mechtersheimer G., Peteresen I., Paulus W., von Deimling A. Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation. Histopathology 2011, 58:1167-1172.
25. Scheie D., Cvancarova M., Mørk S., Skullerud K., Andresen P.A., Benestad I., Helseth E., Meling T., Beiske K. Can morphology predict 1p/19q loss in oligodendroglial tumours?. Histopathology 2008, 53:578-587.
26. Smith M.T. Case for diagnosis. Mil. Med. 1981, 146:567-568. 589.
27. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J.B., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
28. Vajtai I., Sahli R., Kappeler A., Christ E.R., Seiler R.W. Leiomyomatoid angiomatous neuroendocrine tumor (LANT) of the pituitary: a distinctive biphasic neoplasm with primitive secretory phenotype and smooth muscle-rich stroma. Acta Neuropathol. 2006, 111:278-283.
29. Vassella E., Vajtai I., Bandi N., Arnold M., Kocher V., Mariani L. Primer extension based quantitative polymerase chain reaction reveals consistent differences in the methylation status of the MGMT promoter in diffusely infiltrating gliomas (WHO grade II-IV) of adults. J. Neurooncol. 2011, 104:293-303.